Our understanding of the viral suppression and immune restoration following antiretroviral therapy of HIV infected individuals stems mainly from the virologic and immunologic assessment of their peripheral blood samples. However, peripheral blood represents only 2 percent of the total lymphocytes in the body. The remaining lymphocytes reside in the lymphoid organs. The gut-associated lymphoid tissue (GALT) harbors the majority of lymphoid tissue in the body. Therefore, suppression of viral replication and eradication of infected cells in gut lymphoid tissue may be important in containment of HIV-1 infection during highly active anti-retroviral therapy (HAART). However, our knowledge of intestinal mucosal immune responses and viral kinetics in HIV-1 infection is limited. The overall objective of this research proposal is to examine the effects of HAART on the virologic and immunologic outcome in GALT in comparison to peripheral blood in HIV-1 infected patients and to investigate the gender differences in the clinical outcome. We will test the hypothesis that suppression of viral loads and diversity, as well as the repopulation of CD4+ T cells in the gut lymphoid tissue will be important predictors of efficacy of HAART and that molecular correlates of protective mucosal immunity and containment of viral infection in gut lymphoid tissue can be identified. Longitudinal, small intestinal biopsy and peripheral blood samples will be obtained from HIV-1 infected men and women prior to and following HAART. Samples will also be obtained from long-term HIV-infected non-progressors and uninfected healthy controls. Viral suppression and evolution of viral variants will be examined in both the productively infected cell population in intestinal tissue and the latently-infected resting CD4+ T cells isolated from peripheral blood. The quantitative, as well as qualitative extent of CD4+ T cell repopulation will be determined. Mucosal immunity will be examined by measuring virus-specific cytotoxic T cell (CTL) responses. DNA Microarray based analysis of gene expression profiles in gut lymphoid tissue will be performed to identify molecular correlates of better clinical outcome. There are 3 specific aims. (1) To determine the effects of HAART on HIV-1 replication and evolution of viral variants in gut lymphoid tissue of HIV-infected men and women. (2) To determine the effects of HAART on the CD4+ T cell repopulation and HIV-1 specific cytotoxic T cell responses in gut lymphoid tissue of HIV-1 infected patients. (3) To determine the alterations in the host gene expression profiles in intestinal mucosa following HAART to determine pathogenic mechanisms and to identify molecular correlates of clinical outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK061297-03
Application #
6769940
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (20))
Program Officer
Hamilton, Frank A
Project Start
2002-07-01
Project End
2007-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
3
Fiscal Year
2004
Total Cost
$359,707
Indirect Cost
Name
University of California Davis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Jiang, Guochun; Santos Rocha, Clarissa; Hirao, Lauren A et al. (2017) HIV Exploits Antiviral Host Innate GCN2-ATF4 Signaling for Establishing Viral Replication Early in Infection. MBio 8:
Kis, Olena; Sankaran-Walters, Sumathi; Hoque, M Tozammel et al. (2016) HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition. Antimicrob Agents Chemother 60:2771-81
Glavan, T W; Gaulke, C A; Santos Rocha, C et al. (2016) Gut immune dysfunction through impaired innate pattern recognition receptor expression and gut microbiota dysbiosis in chronic SIV infection. Mucosal Immunol 9:677-88
Jiang, Guochun; Dandekar, Satya (2015) Targeting NF-?B signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses 31:4-12
Jiang, Guochun; Mendes, Erica A; Kaiser, Philipp et al. (2015) Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog 11:e1005066
Jiang, Guochun; Mendes, Erica A; Kaiser, Philipp et al. (2014) Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase C?-NF-?B signaling. AIDS 28:1555-66
Nagy, Lauren H; Grishina, Irina; Macal, Monica et al. (2013) Chronic HIV infection enhances the responsiveness of antigen presenting cells to commensal Lactobacillus. PLoS One 8:e72789
Sena, Angela; Grishina, Irina; Thai, Anne et al. (2013) Dysregulation of anti-inflammatory annexin A1 expression in progressive Crohns Disease. PLoS One 8:e76969
Lerner, Paula; Guadalupe, Moraima; Donovan, Richard et al. (2011) The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol 85:4772-82
Shen, Ruizhong; Meng, Gang; Ochsenbauer, Christina et al. (2011) Stromal down-regulation of macrophage CD4/CCR5 expression and NF-?B activation mediates HIV-1 non-permissiveness in intestinal macrophages. PLoS Pathog 7:e1002060

Showing the most recent 10 out of 26 publications